All AbMole products are for research use only, cannot be used for human consumption.

WAY-362450 (Turofexorate isopropyl; XL335) is a synthetic potent agonists of the farnesoid X receptor (FXR). WAY-362450 binds to the ligand-binding domain (LBD) of human FXR. WAY-362450 (XL335) also induced small heterodimer partner (SHP) expression and repressed cholesterol 7alpha-hydroxylase (CYP7A1) and sterol 12 alpha-hydroxylase (CYP8B1) expression. Oral administration of WAY-362450 to LDLR(-/-) mice results in lowering of cholesterol and triglycerides. Furthermore, treatment of wild type C57BL/6 mice with the FXR agonist WAY-362450, attenuated lipopolysaccharide-induced serum amyloid P component and serum amyloid A3 mRNA levels in the liver.
| Molecular Weight | 438.47 |
| Formula | C25H24F2N2O3 |
| CAS Number | 629664-81-9 |
| Solubility (25°C) | DMSO 25 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related Farnesoid X Receptor Products |
|---|
| GW4064
GW4064 is a selective, non-steroidal agonist of the orphan nuclear receptor FXR with EC50 of 15 nM. |
| Chenodeoxycholic acid
Chenodeoxycholic acid is an epimer of ursodeoxycholic acid, which inhibits the production of cholesterol in the liver and absorption in the intestines. |
| Obeticholic Acid (INT-747)
Obeticholic Acid (INT-747) is a potent, orally active, selective farnesoid X receptor (FXR) agonist with an EC50 of 99 nM.May be used in studies related to non-alcoholic steatohepatitis (NASH). |
| Sevelamer HCl
Sevelamer HCl is a phosphate binding drug used to treat hyperphosphatemia via binding to dietary phosphate and prevents its absorption. |
| PX-102
PX-102, also known as PX20606, is a FXR agonist. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
